FREEHOLD, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the "Board of Directors") has authorized a stock repurchase plan (the "Repurchase Plan") of up to $250,000 of Chromocell's common stock ("Common Stock"), which represents approximately 23% of the non-affiliate float based on the closing price of the Company's Co ...